Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9–14 years: results of the long-term extension of the DoRIS randomised trial-Reference-Cited by-同舟云学术

Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9–14 years: results of the long-term extension of the DoRIS randomised trial

Published:2025-02 Issue:2 Volume:13 Page:e319-e328
ISSN:2214-109X
Container-title:The Lancet Global Health
language:en
Short-container-title:The Lancet Global Health

Author:

Watson-Jones Deborah,Changalucha John,Maxwell Caroline,Whitworth Hilary,Mutani Paul,Kemp Troy J,Kamala Beatrice,Indangasi Jackton,Constantine George,Hashim Ramadhan,Mwanzalima David,Wiggins Rebecca,Mmbando Devis,Connor Nicholas,Pavon Miquel A,Lowe Brett,Kapiga Saidi,Mayaud Philippe,de Sanjosé Silvia,Dillner Joakim,Hayes Richard J,Lacey Charles J,Pinto Ligia,Baisley Kathy

Funder

UK Government Foreign Commonwealth & Development Office

Global Challenges Research Fund

Bill & Melinda Gates Foundation

United Kingdom Department of Health & Social Care

UK Research and Innovation Medical Research Council

Wellcome Trust

Publisher

Elsevier BV

Reference29 articles.

1. Status of HPV vaccine introduction and barriers to country uptake;Gallagher;Vaccine,2018

2. Key decision-making factors for human papillomavirus (HPV) vaccine program introduction in low-and-middle-income-countries: global and national stakeholder perspectives;Guillaume;Hum Vaccin Immunother,2022